Aller au contenu principal
Accès ouvert déclaré 2026 article

GATA3 and YBX1 are associated with ER-specific metabolic programs and vulnerabilities in breast cancer

0Citations signalées — pas une note de qualité
8Institutions déclarées
4Pays d’affiliation déclarés

Résumé fourni par la source

Estrogen receptor (ER) status is a key clinical classifier in breast cancer, but its relationship with tumor metabolism remains incompletely understood. We integrated transcriptomic data from 1992 tumors with metabolomic, single-cell, and functional analyses to define ER-associated metabolic programs. ER-positive (ER+ve) tumors exhibited transcriptomic signatures of oxidative metabolism, including fatty acid and branched-chain amino acid catabolism, whereas ER-negative (ER-ve) tumors showed glycolytic and lipogenic reprogramming. Network analysis identified GATA3 and YBX1 as major context-specific regulators associated with ER+ve and ER-ve metabolic states, respectively. Single-cell analyses supported these findings, demonstrating enrichment of GATA3 in ER+ve tumor cells and YBX1 activity in triple-negative breast cancer cells. Functional perturbation and 13C-tracer experiments showed that altering GATA3 or YBX1 expression changed glucose and lipid substrate utilization. Loss of GATA3 increased ER+ve cell sensitivity to glycolytic and lipogenic inhibitors, doxorubicin, and combination treatments. In contrast, YBX1 depletion reduced sensitivity to metabolic inhibitors but enhanced doxorubicin sensitivity in ER-ve cells. Clinically, GATA3 regulon activity was independently associated with prognosis in ER+ve disease, whereas YBX1 regulon activity lacked independent prognostic significance after adjustment for clinical variables. These findings identify GATA3 and YBX1 as ER-specific metabolic regulators linking transcriptional programs, metabolic states, and therapeutic response in breast cancer. Integrative transcriptomic, single-cell and functional analyses identify GATA3 and YBX1 as estrogen receptor-specific regulators linking metabolic reprogramming to therapeutic vulnerability in breast cancer.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
GATA3 and YBX1 are associated with ER-specific metabolic programs and vulnerabilities in breast cancer
Date Crossref
22/08/2026
Éditeur
Springer Science and Business Media LLC
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude et ne compte pas comme une seconde source scientifique indépendante.

Institutions déclarées

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Sujets associés

Cancer, Hypoxia, and MetabolismMetastasis and carcinoma case studiesCancer, Lipids, and Metabolism

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.